Methotrexate Renal Dosing Recommendations
For patients with impaired renal function, reduce methotrexate dose by 50% when creatinine clearance is 20-50 mL/min, and avoid methotrexate entirely when creatinine clearance is <20 mL/min. 1
Dosing Algorithm Based on Renal Function
GFR-Based Dosing Adjustments
- GFR >90 mL/min/1.73 m²: Use normal dose (7.5-25 mg weekly for psoriasis/RA)
- GFR 20-50 mL/min/1.73 m²: Reduce dose by 50%
- GFR <20 mL/min/1.73 m²: Avoid methotrexate; contraindicated
- Patients on dialysis: Contraindicated 1
High-Dose Methotrexate (≥3 g/m²)
For oncologic indications, creatinine clearance must be >60 mL/min before initiating therapy 2. If serum creatinine increases by 50% or more during treatment, measured creatinine clearance must be documented to remain >60 mL/min before continuing therapy, even if the absolute value remains within normal range 2.
Critical Monitoring Requirements
Baseline Assessment
Measure estimated GFR (eGFR) at baseline before initiating methotrexate 1. This is essential because methotrexate is predominantly renally excreted (80-90% unchanged in urine within 24 hours), and impaired clearance dramatically increases toxicity risk, particularly life-threatening myelosuppression 1, 2.
Special Considerations for Test Dosing
A test dose (2.5-5 mg) should be strongly considered in patients with impaired kidney function 3. Follow with complete blood count 5-7 days later to assess individual susceptibility to bone marrow suppression before proceeding to therapeutic dosing 3.
Why Renal Function Matters
Methotrexate elimination is primarily through glomerular filtration and active tubular secretion 2. Myelosuppression is the most important cause of methotrexate-associated death, and this risk increases significantly with renal dysfunction 1. The duration of exposure to methotrexate—not just peak levels—drives toxicity in normal tissues 2.
Important Caveats
eGFR can be unreliable in extremes of body mass (bodybuilders, muscle wasting disorders), where serum creatinine may be elevated despite normal renal function 1. In these cases, measured creatinine clearance may be more appropriate, though research shows calculated clearance using Cockcroft-Gault correlates reasonably well with measured values in most patients 4.
Drug Interactions Affecting Renal Clearance
Weak organic acids that undergo tubular secretion can markedly increase methotrexate serum levels 2. Common culprits include:
- NSAIDs
- Probenecid
- Penicillins
- Salicylates
These medications compete for the same renal tubular secretion pathway and should be avoided or used with extreme caution during methotrexate therapy.
Supportive Care Requirements
Regardless of baseline renal function, all patients require:
- Folic acid supplementation (1 mg daily, 6 days/week, avoiding methotrexate day) to reduce hepatic and GI adverse effects 3
- Adequate hydration for high-dose regimens
- Urinary alkalinization (pH >7.0) for high-dose methotrexate to enhance renal elimination 2
Evidence Quality Note
The British Association of Dermatologists 2016 guideline 1 provides the most explicit renal dosing recommendations (strength D, level 3 evidence), extrapolated from rheumatology literature. The FDA label 2 provides specific requirements for high-dose methotrexate but less granular guidance for low-dose regimens. Recent pharmacometric analyses 5 confirm that time-dependent serum creatinine is a clinically significant covariate affecting methotrexate clearance, supporting the importance of ongoing renal monitoring beyond baseline assessment.